This finding is aligned with other literature studies, where 68Ga-PSMA-11 PET/CT was found to modify intermediate and/or high-risk PCa patients’ staging compared to CI in a range of 28% to 55% [7,14,22,23,24]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.